Latest

India has the second highest rate of diabetes in the world, and with the monthly fee reduced to $14, why are GLP-1 weight loss drugs still not selling well?

India has the second highest rate of diabetes in the world, and with the monthly fee reduced to $14, why are GLP-1 weight loss drugs still not selling well?

The Indian weight-loss drug market is serving as a cautionary tale for the global pharmaceutical industry regarding market expectations. Despite the large-scale generic production of GLP-1 drugs in India and prices dropping to $14 per month, sales have fallen far short of expectations, revealing deeper cultural, social, and regulatory barriers
Admin